{
    "id": "correct_subsidiary_00046_1",
    "rank": 85,
    "data": {
        "url": "https://investors.soleno.life/node/8596/html",
        "read_more_link": "",
        "language": "en",
        "title": "SEC Filing – Soleno Therapeutics Inc.",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://investors.soleno.life/sites/g/files/knoqqb85991/files/Soleno_logo.png",
            "https://cdn.kscope.io/5a2bd7163154f1e9aeb197b59d0d9350-pkf1.jpg",
            "https://cdn.kscope.io/5a2bd7163154f1e9aeb197b59d0d9350-pkfsignature.jpg",
            "https://cdn.kscope.io/5a2bd7163154f1e9aeb197b59d0d9350-document8image1.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "•\n\nIf such termination or resignation occurs within six (6) months prior to, or twelve (12) months following, a Change in Control of the Company: (i) continuing payments of severance pay at a rate equal to Dr. Bhatnagar’s base salary rate for eighteen (18) months from the date of such termination without Cause or resignation for Good Reason; (ii) if Dr. Bhatnagar elects continuation coverage pursuant to COBRA, then the Company will reimburse Dr. Bhatnagar on the last day of each month for a period ending eighteen (18) months after Dr. Bhatnagar’s termination date for the COBRA premiums paid during such period for such coverage (at the coverage levels in effect immediately prior to Dr. Bhatnagar’s termination); (iii) a payment equal to one hundred fifty percent (150%) the annual target bonus opportunity for the year in which Dr. Bhatnagar is terminated without Cause or resigns for Good Reason; and (iv) one hundred percent (100%) of any unvested equity awards held by Dr. Bhatnagar as of the date of such termination without Cause or resignation for Good Reason shall immediately vest and become fully exercisable; and\n\n•\n\nIf Mr. Wondka’s termination or resignation occurs within three (3) months prior to, or six (6) months following, a Change in Control of the Company: (i) continuing payments of severance pay at a rate equal to Mr. Wondka’s base salary rate for twelve (12) months from the date of such termination without Cause or resignation for Good Reason; (ii) if Mr. Wondka elects continuation coverage pursuant to COBRA, then the Company will reimburse Mr. Wondka on the last day of each month for a period ending twelve (12) months after Mr. Wondka’s termination date for the COBRA premiums paid during such period for such coverage (at the coverage levels in effect immediately prior to Mr. Wondka’s termination); (iii) a payment equal to one hundred percent (100%) the annual target bonus opportunity for the year in which Mr. Wondka is terminated without Cause or resigns for Good Reason; and (iv) one hundred percent (100%) of any unvested equity awards held by Mr. Wondka as of the date of such termination without Cause or resignation for Good Reason shall immediately vest and become fully exercisable.\n\n(1)\n\nRepresents shares of common stock outstanding or issuable within 60 days of April 12, 2017, consisting of: (a) 16,674,428 shares of common stock held by Vivo Ventures Fund, V, L.P., consisting of (W) 14,076,263 shares of outstanding Common Stock, of which 7,154,140 shares of Common Stock are being registered as part of this offering, (X) zero shares of common stock subject to outstanding options that are vested and exercisable within sixty days of April 12, 2017, (Y) 1,255,019 shares of common stock issuable upon the exercise of warrants (assuming an exercise date of April 12, 2017), and (Z) 1,343,146 shares of Common Stock are potentially issuable upon the achievement of certain milestones within sixty days of April 12, 2017 and are being registered as part of this offering; (b) 195,918 shares of common stock held by Vivo Ventures V Affiliates Fund, LP., consisting of (W) 165,373 shares of outstanding Common Stock, of which 84,140 shares of Common Stock are being registered as part of this offering, (X) zero shares of common stock subject to outstanding options that are vested and exercisable within sixty days of April 12, 2017, (Y) 14,726 shares of common stock issuable upon the exercise of warrants (assuming an exercise date of April 12, 2017), and (Z) 15,819 shares of Common Stockare potentially issuable upon the achievement of certain milestones within sixty days of April 12, 2017 and are being registered as part of this offering; (c) 231,273 shares of common stock held by BDF IV Annex Fund, L.P., consisting of (W) 227,068 shares of outstanding common stock, (X) zero shares of common stock subject to outstanding options that are vested and exercisable within sixty days of April 12, 2017, and (Y) 4,205 shares of common stock issuable upon the exercise of warrants (assuming an exercise date of April 12, 2017); (d) 167,945 shares of common stock held by Biotechnology Development Fund IV, L.P., consisting of (W) 166,943 shares of outstanding common stock, (X) zero shares of common stock subject to outstanding options that are vested and exercisable within sixty days of April 12, 2017, and (Y) 1,002 shares of common stock issuable upon the exercise of warrants (assuming an exercise date of April 12, 2017); and (e) 3,093 shares of common stock held by Biotechnology Development Fund IV Affiliates, L.P., consisting of (W) 3,076 shares of outstanding common stock, (X) zero shares of common stock subject to outstanding options that are vested and exercisable within sixty days of April 12, 2017, and (Y) 17 shares of common stock issuable upon the exercise of warrants (assuming an exercise date of April 12, 2017). Vivo Ventures V LLC (Vivo V LLC), is the sole general partner of both of Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. (Vivo V Funds), and may be deemed to beneficially own the common stock of Soleno Therapeutics owned by the Vivo V Funds. Vivo V LLC disclaims beneficial ownership of the shares of Soleno Therapeutics held by each of the Vivo V Funds, except to the extent of its pecuniary interest therein. BioAsia Investments IV, LLC (BAI IV), is the sole general partner of Biotechnology Development Fund IV, LP, Biotechnology Development Fund IV Affiliates, L.P., BDF IV Annex Fund, L.P. (BDF IV Funds) and may be deemed to beneficially own the common stock of Soleno Therapeutics owned by the BDF IV Funds. BAI IV"
    }
}